JB Pharma reports strong Q2 and H1 FY26 financials

J.B. Chemicals & Pharmaceuticals Limited reported an 8% increase in revenue to INR 1,085 crores for Q2 FY26 compared to INR 1,001 crores in Q2 FY25. For H1 FY26, revenue grew 9% to INR 2,179 crores. Operating EBITDA saw a healthy rise of 12% to INR 319 crores in Q2 FY26, with margins improving to 29.4% from 28.4% in the prior year. Profit after Tax (PAT) increased by 19% to INR 208 crores in Q2 FY26, and 17% to INR 410 crores for H1 FY26.

The domestic formulations business was a key driver, growing 9% year-on-year to INR 644 crores in Q2 FY26. This segment constituted 61% of the overall turnover in H1 FY26, up from 59% in H1 FY25. The company outperformed the Indian Pharmaceutical Market (IPM), with a 12% growth versus IPM's 8%. The Sporlac franchise, a recent acquisition, nearly doubled in three years, reaching INR 153 crores in MAT Sept’25 sales, while the Razel franchise crossed INR 100 crores.

International business revenue grew 7% to INR 441 crores in Q2 FY26, with the CDMO division showing strong performance, increasing by 20% to INR 113 crores. Cash flows remained strong, with gross debt reduced to INR 7 crores as of September 30, 2025. The ophthalmology portfolio from Novartis, smoothly integrated, also contributed to growth, with sales increasing 10% to INR 115 crores in H1 FY26.